Cancer cells treated with Amy-F showed a considerable reduction in the CD4, CD80 expression, whereas, induced elevation in CD8 and NKG2D expression was observed in Amy-F treated BCCs when compared to the RT group. This evidence concerns the gene CD80 and cancer.